NDC properties for "1250 MG Androgel 0.0162 MG/MG Topical Gel" (RxCUI 1597121)
About this data
The tables show NDC propoerties for 1250 MG Androgel 0.0162 MG/MG Topical Gel with the RxCUI 1597121
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for 1250 MG Androgel 0.0162 MG/MG Topical Gel (RxCUI 1597121)
| MMSL_CODE | BD29532 |
|---|---|
| NDA | NDA022309 |
| RxCUI | 1597121 |
| SPL_SET_ID | 8677ba5b-8374-46cb-854c-403972e9ddf3 |
| SPL_SET_ID | f4e8d29b-8707-4d47-e053-2a95a90aecee |
| VUID | 4032991 |
| Prescribable Synonym | AndroGel 1.62 % (20.25MG / 1.25GM) Transdermal Gel |
| RXNAV_STR | Androgel 1.62 % Transdermal Gel, 1.25 GM |
| RxNorm Name | 1250 MG testosterone 0.0162 MG/MG Topical Gel [Androgel] |
| RxNorm Synonym | 1250 MG Androgel 0.0162 MG/MG Topical Gel |
| RxNorm Synonym | Androgel 1.62 % Transdermal Gel, 1.25 GM |
| Related queries | Interactions (for RxCUI 1597121) |
NDC Properties
NDC Item 00051846212
| NDC 9 | 0051-8462 |
|---|---|
| NDC 10 | 0051-8462-12 |
| NDC Item | 00051846212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 697433 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2025-05-01 |
| Marketing effective time low | 2011-04-29 |
| Marketing status | COMPLETED |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 0051-8462 |
NDC Item 00051846231
| NDC 9 | 0051-8462 |
|---|---|
| NDC 10 | 0051-8462-31 |
| NDC Item | 00051846231 |
| Packaging | 30 PACKET in 1 CARTON (0051-8462-31) / 1.25 g in 1 PACKET (0051-8462-12) |
| DCSA | CIII |
| FDA SPL set id | 697433 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2025-05-01 |
| Marketing effective time low | 2011-04-29 |
| Marketing status | COMPLETED |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 0051-8462 |
NDC Item 17139056212
| NDC 9 | 17139-562 |
|---|---|
| NDC 10 | 17139-562-12 |
| NDC Item | 17139056212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 756537 |
| Labeler | ASCEND Therapeutics U.S., LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2023-02-17 |
| Marketing status | ACTIVE |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 17139-562 |
NDC Item 00051846212
| NDC 9 | 0051-8462 |
|---|---|
| NDC 10 | 0051-8462-12 |
| NDC Item | 00051846212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 697433 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2025-05-01 |
| Marketing effective time low | 2011-04-29 |
| Marketing status | COMPLETED |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 0051-8462 |
NDC Item 00051846231
| NDC 9 | 0051-8462 |
|---|---|
| NDC 10 | 0051-8462-31 |
| NDC Item | 00051846231 |
| Packaging | 30 PACKET in 1 CARTON (0051-8462-31) / 1.25 g in 1 PACKET (0051-8462-12) |
| DCSA | CIII |
| FDA SPL set id | 697433 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2025-05-01 |
| Marketing effective time low | 2011-04-29 |
| Marketing status | COMPLETED |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 0051-8462 |
NDC Item 17139056212
| NDC 9 | 17139-562 |
|---|---|
| NDC 10 | 17139-562-12 |
| NDC Item | 17139056212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 756537 |
| Labeler | ASCEND Therapeutics U.S., LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2023-02-17 |
| Marketing status | ACTIVE |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 17139-562 |
NDC Item 00051846212
| NDC 9 | 0051-8462 |
|---|---|
| NDC 10 | 0051-8462-12 |
| NDC Item | 00051846212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 697433 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2025-05-01 |
| Marketing effective time low | 2011-04-29 |
| Marketing status | COMPLETED |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 0051-8462 |
NDC Item 00051846231
| NDC 9 | 0051-8462 |
|---|---|
| NDC 10 | 0051-8462-31 |
| NDC Item | 00051846231 |
| Packaging | 30 PACKET in 1 CARTON (0051-8462-31) / 1.25 g in 1 PACKET (0051-8462-12) |
| DCSA | CIII |
| FDA SPL set id | 697433 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2025-05-01 |
| Marketing effective time low | 2011-04-29 |
| Marketing status | COMPLETED |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 0051-8462 |
NDC Item 17139056212
| NDC 9 | 17139-562 |
|---|---|
| NDC 10 | 17139-562-12 |
| NDC Item | 17139056212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 756537 |
| Labeler | ASCEND Therapeutics U.S., LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2023-02-17 |
| Marketing status | ACTIVE |
| NDA | NDA022309 |
| Related queries | Properties for NDC 9 17139-562 |